ES2195121T3 - Uso de una sal farmaceuticamente aceptable de (3r,2'r)-3-((ciclopentilhidroxifenilacetil)oxi)-1,1-dimetilpirrolidinio para la preparacion de un medicamento. - Google Patents

Uso de una sal farmaceuticamente aceptable de (3r,2'r)-3-((ciclopentilhidroxifenilacetil)oxi)-1,1-dimetilpirrolidinio para la preparacion de un medicamento.

Info

Publication number
ES2195121T3
ES2195121T3 ES97911049T ES97911049T ES2195121T3 ES 2195121 T3 ES2195121 T3 ES 2195121T3 ES 97911049 T ES97911049 T ES 97911049T ES 97911049 T ES97911049 T ES 97911049T ES 2195121 T3 ES2195121 T3 ES 2195121T3
Authority
ES
Spain
Prior art keywords
rent
preparation
pirrolidiny
ciclopentilhydroxifenilacetil
oxi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97911049T
Other languages
English (en)
Inventor
Christian R Noe
Ernst Mutschler
Gunter Lambrecht
Michael Elgert
Sittah Czeche
Magali Waelbroeck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2195121T3 publication Critical patent/ES2195121T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

SE EXPONEN ESTERES ENANTIOMEROS PUROS, Y POR CONSECUENCIA LOS ENANTIOMEROS CONFIGURADOS EN (3R, 2''R) -, (3S, 2''R) - Y (3S, 2''S) -, DE FORMA GENERAL (I) EN LA QUE R 1 SIGNIFICA UN RADICAL CICLOALQUILO - C 3 - C 9 , MONO -, BI - O TRICICLICO, OPTATIVAMENTE SUSTITUIDO POR UNO O MAS RADICALES ALQUILO - C 1 - C 6 , ALQUENILO - C 2 - C 6 Y/O ALQUINILO - C 2 - C 6 , Y/O POR UNO O VARIOS ATOMOS DE HALOGENO, TALES COMO FLUOR, CLORO, BROMO O YODO; R 2 SIGNIFICA UN RADICAL ALQUILO - C 1 - C 6 , ALQUENILO C 2 - C 6 Y/O ALQUINILO - C 2 C 6 , OPTATIVAMENTE SUSTITUIDO POR UNO O VARIOS ATOMOS DE HALOGENO, TALES COMO FLUOR, CLORO, BROMO O YODO; R 3 SIGNIFICA UN RADICAL ALQUILO - C 1 - C 6 , ALQUENILO - C 2 - C 6 Y/O ALQUINILO - C 2 - C 6 , OPTATIVAMENTE SUSTITUIDO POR UNO O VARIOS ATOMOS DE HALOGENO, TALES COMO FLUOR, CLORO, BROMO O YODO; AR SIGNIFICA UN COMPUESTO AROMATICO O UN COMPUESTO HETEROAROMATICO QUE CONTIENE NITROGENO, AZUFRE U OXIGENO COMO HETEROATOMO; N ES UN NUMERO ENTERO IGUAL A 1, 2 O 3; A ESUN ANION DE UN ACIDO FARMACOLOGICAMENTE ADMISIBLE. SE EXPONE IGUALMENTE LA PREPARACION DE ESTOS COMPUESTOS Y SU USO EN MEDICAMENTOS.
ES97911049T 1996-11-11 1997-11-11 Uso de una sal farmaceuticamente aceptable de (3r,2'r)-3-((ciclopentilhidroxifenilacetil)oxi)-1,1-dimetilpirrolidinio para la preparacion de un medicamento. Expired - Lifetime ES2195121T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT197396 1996-11-11

Publications (1)

Publication Number Publication Date
ES2195121T3 true ES2195121T3 (es) 2003-12-01

Family

ID=3525062

Family Applications (2)

Application Number Title Priority Date Filing Date
ES97911049T Expired - Lifetime ES2195121T3 (es) 1996-11-11 1997-11-11 Uso de una sal farmaceuticamente aceptable de (3r,2'r)-3-((ciclopentilhidroxifenilacetil)oxi)-1,1-dimetilpirrolidinio para la preparacion de un medicamento.
ES03005232T Expired - Lifetime ES2407135T3 (es) 1996-11-11 1997-11-11 Uso de (3S,2'R)-glicopirronio como medicamento

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES03005232T Expired - Lifetime ES2407135T3 (es) 1996-11-11 1997-11-11 Uso de (3S,2'R)-glicopirronio como medicamento

Country Status (18)

Country Link
US (1) US6307060B1 (es)
EP (3) EP0937041B1 (es)
JP (1) JP2001504459A (es)
CN (1) CN100391942C (es)
AT (1) ATE238280T1 (es)
AU (1) AU745331B2 (es)
CA (1) CA2271276C (es)
DE (1) DE59709927D1 (es)
DK (2) DK0937041T3 (es)
ES (2) ES2195121T3 (es)
HU (1) HU228273B1 (es)
NO (1) NO314354B1 (es)
NZ (1) NZ336202A (es)
PL (1) PL195520B1 (es)
PT (2) PT1371645E (es)
RU (1) RU2238936C2 (es)
SI (2) SI0937041T1 (es)
WO (1) WO1998021183A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0937041T3 (da) * 1996-11-11 2003-08-11 Christian R Noe Anvendelse af et farmaceutisk egnet salt af (3R,2'R)-3-[(cyclopentil-hydroxyphenylacetyl)oxyl]-1,1-dimethyl-pyrrolidinium til fremstilling af et lægemiddel
US6613795B2 (en) 1996-11-11 2003-09-02 Christian Noe Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
AU2001271027B2 (en) 2000-07-11 2005-07-07 Msd K.K. Ester derivatives
ES2206021B1 (es) * 2002-04-16 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirrolidinio.
AT412088B (de) 2002-12-18 2004-09-27 Pharmacon Forschung & Beratung Gmbh Verfahren zur herstellung der r,r oder s,s konfigurierten glycopyrronium-isomere
AU2002347552A1 (en) * 2002-12-23 2004-07-14 Ranbaxy Laboratories Limited 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists
DE60313898T2 (de) * 2003-04-10 2008-01-17 Ranbaxy Laboratories, Ltd. Substituierte azabicyclo hexane derivate als muscarin rezeptor antagonisten
PE20050231A1 (es) * 2003-06-24 2005-05-20 Novartis Ag Derivados de piperidinium y pirrolidinium como antagonistas del receptor muscarinico m3
RU2438660C2 (ru) 2004-02-06 2012-01-10 Меда Фарма Гмбх Унд Ко. Кг Комбинация и фармацевтический препарат для лечения воспалительных и обструктивных заболеваний дыхательных путей
GB0411056D0 (en) * 2004-05-18 2004-06-23 Novartis Ag Organic compounds
CA2568834A1 (en) * 2004-06-29 2006-01-12 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising steroids and an anticholinergic
EP1616567A1 (en) * 2004-07-16 2006-01-18 Boehringer Ingelheim Pharma GmbH & Co.KG Medicaments for inhalation comprising PDE IV inhibitors and glycopyrrolate salts
EP1781607A2 (en) * 2004-08-19 2007-05-09 Ranbaxy Laboratories Limited Pyrrolidine derivatives as muscarinic receptor antagonists
GB0428418D0 (en) 2004-12-24 2005-02-02 Novartis Ag Organic compounds
GB0428416D0 (en) 2004-12-24 2005-02-02 Novartis Ag Organic compounds
GB0504463D0 (en) * 2005-03-03 2005-04-13 Arakis Ltd Method of crystallisation and purification
ES2570332T3 (es) * 2005-03-16 2016-05-17 Meda Pharma Gmbh & Co Kg La combinación de anticolinérgicos y antagonistas del receptor de leucotrieno para el tratamiento de enfermedades respiratorias
TW200722418A (en) * 2005-04-20 2007-06-16 Astrazeneca Ab Novel compounds
EP1879571A1 (de) * 2005-04-23 2008-01-23 Boehringer Ingelheim International GmbH Arzneimittelkombination für die inhalation enthaltend neben einem anticholinergikum ein betamimetikum und ein steroid
NZ591969A (en) * 2005-12-21 2012-05-25 Meda Pharma Gmbh & Co Kg Combination of anticholinergics, glucocorticoids, beta2-adrenoceptor agonists, PDE 4 inhibitor and antileukotriene for the treatment of inflammatory diseases
GB0613161D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
EA017627B1 (ru) 2008-05-13 2013-01-30 Астразенека Аб Хинуклидиновые производные в качестве антагонистов мускаринового м3 рецептора
MX337126B (es) * 2009-05-29 2016-02-12 Pearl Therapeutics Inc Administracion respiratoria de agentes activos.
US8742131B2 (en) 2010-01-28 2014-06-03 Theron Pharmaceuticals, Inc. 7-azoniabicyclo [2.2.1] heptane derivatives, methods of production, and pharmaceutical uses thereof
CA2802615A1 (en) * 2010-06-14 2011-12-22 Chiesi Farmaceutici S.P.A. Process for the preparation of glycopyrronium chloride
ES2528957T3 (es) * 2010-06-14 2015-02-13 Chiesi Farmaceutici S.P.A. Forma cristalina del cloruro de glicopirronio
JOP20120023B1 (ar) 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
CN102627595A (zh) * 2012-03-09 2012-08-08 徐奎 一种制备格隆溴铵的方法
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
EP3473615B1 (en) 2013-02-28 2022-01-19 Journey Medical Corporation Glycopyrrolate salts
KR102074543B1 (ko) 2013-03-14 2020-02-06 노파르티스 아게 분무-블렌딩을 통한 분무-건조 제제의 탈무정형화
US9452139B2 (en) 2013-03-14 2016-09-27 Novartis Ag Respirable agglomerates of porous carrier particles and micronized drug
CN104586841A (zh) * 2013-10-30 2015-05-06 中国药科大学 (3r,2’r)-格隆溴铵作为m3毒蕈碱性受体拮抗剂在制药中的用途
US9926270B2 (en) 2014-08-20 2018-03-27 Dermira, Inc. Process for production of glycopyrronium tosylate
EP3237378B1 (en) * 2014-12-24 2018-09-26 Laboratorios Lesvi, S.L. Process for preparing (3rs)-3-[(2sr)-(2-cyclopentyl-2-hydroxy-2-phenylacetyl)oxy]-1,1-dimethylpyrrolidinium bromide
CN107304178B (zh) * 2016-04-21 2020-03-27 辽宁药联制药有限公司 一种毒蕈碱受体拮抗剂格隆溴铵手性对映体的制备方法
EP3494106B1 (en) * 2016-08-02 2022-07-20 Journey Medical Corporation Processes for making, and methods of using, glycopyrronium compounds

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2882276A (en) * 1959-04-14 Certain esters of amino alcohols
US2980693A (en) * 1961-04-18 Methods for producing same
CA625276A (en) * 1961-08-08 D. Lunsford Carl Esters of amino alcohols
US3157671A (en) * 1964-11-17 Ljl-diethyl-a-hydroxypyrrolidimum
CA629039A (en) * 1961-10-10 A.H. Robins Company 1-substituted-3-pyrrolidyl benzilates
GB821436A (en) * 1956-02-22 1959-10-07 Parke Davis & Co 3-pyrrolidinyl benzilates
CH375358A (de) * 1957-06-17 1964-02-29 Robins Co Inc A H Verfahren zur Herstellung von Estern von N-substituierten 3-Pyrrolidinolen
US2958028A (en) * 1957-11-01 1960-10-25 Collins Radio Co Remote control system
US2956062A (en) * 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
US3185702A (en) * 1959-03-16 1965-05-25 Lunsford Carl Dalton Basic esters of 3-aryl-3-pyrrolidinols
GB885430A (en) * 1960-08-17 1961-12-28 Loewe Opta Ag Arrangement for receiving stereophonic transmissions
GB1170831A (en) * 1967-02-01 1969-11-19 Robins Co Inc A H O-Substituted Pyrrolidinols and S-Substituted Thiopyrrolidinols and Processes for their Preparation
US3691198A (en) * 1970-12-21 1972-09-12 Cpc International Inc Synthesis of 1-substituted-3-halopyrrolidines
FI49713C (fi) * 1974-05-15 1975-09-10 Medica Pharma Co Ltd Terapeuttisesti tehokkaan erytro-1-metyyli-3-pyrrolidinyyli-alfa-syklo -pentyylimandelaattimetobromidin valmistusmenetelmä.
US4208423A (en) * 1978-11-24 1980-06-17 Syntex Inc. Anticholinergic bronchodilators
US4228171A (en) * 1979-03-05 1980-10-14 Syntex (U.S.A.) Inc. Antichlorinergic bronchodilators
SU1416056A3 (ru) * 1983-01-21 1988-08-07 Алкалоида Ведьесети Дьяр (Инопредприятие) Способ получени производных пирролидина или их солей с неорганической кислотой
US4721722A (en) * 1985-07-12 1988-01-26 United Pharmaceuticals, Inc. Anti-spasmodic agents containing quaternary nitrogen
EP0823423B1 (en) * 1995-04-28 2004-06-16 Banyu Pharmaceutical Co., Ltd. 1,4-disubstituted piperidine derivatives
WO1998000133A1 (en) 1996-07-01 1998-01-08 Sepracor, Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (s,s)-glycopyrrolate
EP0909172A4 (en) 1996-07-01 1999-06-09 Sepracor Inc METHODS AND COMPOSITIONS FOR TREATING URINARY INCONTINENCE WITH ENANTIOMERIC ENRICHED (R, s) -GLYCOPYRROLATE
DK0937041T3 (da) * 1996-11-11 2003-08-11 Christian R Noe Anvendelse af et farmaceutisk egnet salt af (3R,2'R)-3-[(cyclopentil-hydroxyphenylacetyl)oxyl]-1,1-dimethyl-pyrrolidinium til fremstilling af et lægemiddel
US6603808B1 (en) 1999-07-22 2003-08-05 Compaq Information Technologies Group, L.P. Dual mode phone line networking modem utilizing conventional telephone wiring

Also Published As

Publication number Publication date
PT937041E (pt) 2003-09-30
US6307060B1 (en) 2001-10-23
CA2271276A1 (en) 1998-05-22
CN100391942C (zh) 2008-06-04
NO991056D0 (no) 1999-03-03
HUP9903791A2 (hu) 2000-03-28
HU228273B1 (en) 2013-02-28
RU2238936C2 (ru) 2004-10-27
PL195520B1 (pl) 2007-09-28
PT1371645E (pt) 2013-05-21
ATE238280T1 (de) 2003-05-15
EP1371645A1 (de) 2003-12-17
EP0937041A1 (de) 1999-08-25
EP1371645B1 (de) 2013-02-20
HK1061023A1 (en) 2004-09-03
SI1371645T1 (sl) 2013-07-31
PL332595A1 (en) 1999-09-27
CA2271276C (en) 2009-01-13
AU745331B2 (en) 2002-03-21
DK1371645T3 (da) 2013-06-03
JP2001504459A (ja) 2001-04-03
ES2407135T3 (es) 2013-06-11
AU4856097A (en) 1998-06-03
HUP9903791A3 (en) 2001-10-29
EP1369414A1 (de) 2003-12-10
NO991056L (no) 1999-05-11
DE59709927D1 (de) 2003-05-28
DK0937041T3 (da) 2003-08-11
CN1237159A (zh) 1999-12-01
SI0937041T1 (en) 2003-10-31
EP0937041B1 (de) 2003-04-23
NO314354B1 (no) 2003-03-10
WO1998021183A1 (de) 1998-05-22
NZ336202A (en) 2000-10-27

Similar Documents

Publication Publication Date Title
ES2195121T3 (es) Uso de una sal farmaceuticamente aceptable de (3r,2'r)-3-((ciclopentilhidroxifenilacetil)oxi)-1,1-dimetilpirrolidinio para la preparacion de un medicamento.
DK0562956T3 (da) Hidtil ukendte naphthylalkylaminer, fremgangsmåde til fremstilling heraf og farmaceutiske midler, som indeholder dem
ES2123039T3 (es) Nuevas 3-(hidroxi-bencilidenil)-indolin-2-onas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen.
UY26244A1 (es) Nuevos derivados de quinuclidina y composiciones farmacéuticas que los contienen.
AU8794291A (en) New oxazolopyridine derivatives, processes for preparing these and pharmaceutical compositions containing them
ES2193142T3 (es) Uso de benzotiofenos para el tratamiento de hipercolesterolemia.
NO954146L (no) Belagte farmasöytiske preparater
ES2126766T3 (es) 7-azaindol-3-ilcarboxiamidas de tropilo como agente antitusivo.
ES2081178T3 (es) Compuestos anti-tumorales que contienen anillos quinazolina y tetrazol.
ES2095942T3 (es) Derivados de bencenoacetamida inhibidores del vih.
ES2159922T3 (es) Nuevos derivados de bencimidazol, de benzoxazol y de benzotiazol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES2118203T3 (es) Nuevos derivados benzopiranicos, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
TNSN97014A1 (fr) Piperidones, procedes pour leur preparation et compositions pharmaceutiques les contenant.
ES2188743T3 (es) Compuestos de acido pirrolidinilhidroxamico y procedimiento de produccion de los mismos.
ES2153019T3 (es) Derivados de benzo-dioxano, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES2116612T3 (es) Nuevas bis-naftalimidas para el tratamiento del cancer.
ES2112483T3 (es) 4-aril-4-hidroxi-tetrahidropiranos y 3-aril-3-hidroxi-tetrahidrofuranos como inhibidores de 5-lipoxigenasa.
ES2183492T3 (es) Nuevos derivados de nitrono,su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES2153457T3 (es) Amino-alquil-benzoxazolinonas y benzotiazolinonas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen.
DK0564358T3 (da) 3-aminochroman-spiro-derivater, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende sådanne
ES2172023T3 (es) Nuevos derivados tetrahidro-piridinicos sustituidos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES2077473T3 (es) Nuevos compuestos tiocromanicos, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
ES2130548T3 (es) Nuevos derivados alquil-amino-indanos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES2157539T3 (es) Derivados del benzopirano, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES2078076T3 (es) Soluciones estabilizadas de acidos percarboxilicos y procedimiento para su preparacion.